SIETES :: 93019 citas

Resultados de la búsqueda por NEFROPATÍA DIABÉTICA REFINAR BÚSQUEDA

1.

Pasternak B, Wintzell V, Melbye M, Eliasson B, Svensson A-M, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Svanström H, Ueda P. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. BMJ 2020;369:29 de abril. [Ref.ID 103626]

2.

Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2018:9 de noviembre. [Ref.ID 102850]

3.

Anónimo. Gilead announces promising trial data for hepatitis C combination drug, setbacks for pulmonary artery hypertension and diabetic kidney disease treatment. DIA Daily 2016:4. [Ref.ID 100839]

4.

Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, Rosano GM, Davis BR, Ridao M, Zaragoza A, Montero-Corominas D, Tobías A, de la Fuente-Honrubia C, Tabarés-Seisdedos R, Hutton B. Cardiovascular and renal outcomes of renin–angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses. PLOS Medicine 2016:8 de marzo. [Ref.ID 100213]

5.

Bangalore S, Fakheri R, Toklu B, Messerli FH. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ 2016;352:i438. [Ref.ID 100061]

6.

Majumdar SR. Antihypertensive treatments for adults with type 2 diabetes. BMJ 2016;352:i560. [Ref.ID 100052]

7.

Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA, for the AMETHYST-DN Investigators. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA 2015;314:151-61. [Ref.ID 99346]

8.

Winkelmayer WC. Treatment of hyperkalemia: from "hyper K" striketout to home run?. JAMA 2015;314:129-30. [Ref.ID 99345]

9.

Greenland P, Lauer MS. Cholesterol lowering in 2015: still answering questions about how in whom. JAMA 2015;314:127-8. [Ref.ID 99344]

10.

Hung S-C, Chang Y-K, Liu J-S, Kuo KL, Chen YH, Hsu CC, Tarng DC. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. The Lancet Diabetes & Endocrinology 2015;3:605-14. [Ref.ID 99203]

11.

Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, Wiebe N, Ruospo M, Wheller DC, Stripooli GFM. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet 2015;385:2047-56. [Ref.ID 99157]

12.

Jafar TH, Assam PN. Dual RAAS blockade for kidney failure: hope for the future. Lancet 2015;385:2018-20. [Ref.ID 99154]

13.

Perry TL. Scant evidence on the effectiveness of metformin in type 2 diabetes. BMJ 2015;350:h2650. [Ref.ID 99116]

14.

de Zeeuw D. The end of dual therapy with renin-angiotensin-aldosterone system blockade?. N Engl J Med 2013;369:1960-2. [Ref.ID 96540]

15.

Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P, for the VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892-903. [Ref.ID 96537]

16.

Slomski A. Avoiding hypoglycemia at all costs is crucial for some with diabetes. JAMA 2013;309:2536-7. [Ref.ID 95732]

17.

Perkovic V, Heerspink HL, Chalmers J, Woodward M, Jun M, Li Q, MacMahon SC, Cooper ME, Hamet P, Marre M, Mogensen CE, Poulter N, Mancia G, Cass A, Patel A, Zoungas S. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013;83:517-23. [Ref.ID 95115]

18.

The DCCT/EDIC Research Group. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011;365:2366-76. [Ref.ID 91982]

19.

House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, Dresser GK, Spence JD. Effect of B-vitamin therapy on progression of diabetic nephropathy. A randomized controlled trial. JAMA 2010;303:1603-9. [Ref.ID 88399]

20.

Tu ST, Chang S-J, Chen J-F, Tien KJ, Hsiao JY, Chen H-C, Hsieh MC. Prevention of diabetic nephropathy by tight target control in an Asian population with type 2 diabetes mellitus. A 4-year prospective analysis. Arch Intern Med 2010;170:155-61. [Ref.ID 87773]